Revolution Medicines Receives Landmark FDA Drug Approval in Pancreatic Cancer
MedCity News
·
·
2 views
FDA approval of Revolution Medicines’ daraxonrasib, brand name Rasonque, makes the molecule the first RAS inhibitor approved for treating pancreatic adenocarcinoma, the most common type of pancreatic cancer. The speedy regulatory nod specifically covers advanced cases of this type of cancer, which has had limited treatment options. The post Revolution Medicines Receives Landmark FDA Drug Approval in Pancreatic Cancer appeared first on MedCity News.
The Journal of Healthcare Contracting 
Three Men On A Boat 
Hospital Management 
Dr. K. P. V. Rao's Health Blog 
Mozocare